Kevin Norrett: I might add just one thing there in that, you know, our assessment of the current products and development for siRNA, we’re certainly great – there’s 400 products in development. So bear in mind, there may be some variation in this, but we see greater and 80% of them, including the two or three most common modifications, which are the two primal methyl and the two times, as well as the phosphonothioate on. So at the end of the day, that’s what we wanted to demonstrate our ability to do that at times. And that was the first step. And we’ll continue to build upon that as the modifications come out.
Stephen Dilly: And we put the slide deck from TIDES up on our website. I think the presentation is going to be up within the next day or so, which is worth a look if you’ve got time.
Chad Wiatrowski: Awesome. Yes. Looking forward to that and to the KOL event in December. Ahead of that event, are there any details you can share on John Maraganore opinion on the need for the ECO Synthesis? Was he involved in that strategy update or was he just added to the strategic advisory board recently? Thanks.
Kevin Norrett: We’ve been talking to him for a little while. I mean, he’s always told me that yes, he was saying we need an enzymatic solution even before he left being CEO of Alnylam a couple of years ago. And he’s very much on board with what we’re trying to do. But what we also need is rather than sort of just cheerleaders, we need people to keep us honest, in terms of what it would really take for someone to adopt this, this methodology, because, I was super serious about what I said in my comments, prepared comments, that there are going to be people sitting there weighing the decision about do I go the old safe tried route, the phosphoramidite chemistry and eat up the cost? Or do I try this new thing. And we’ve got to show I mean, reliability and dependability, and we’ve got a couple of books.
Purity is going to be one of them. And the reduced capital investment is going to be another one. But they’re all has to be based on rigor and meeting the specification, and doing it dependably and doing it repetitively. So all of that is front of mind and having people that are really sat in that seat advising us is super useful.
Chad Wiatrowski: Thanks again for the questions.
Operator: Thank you. Our next question comes from the line of Brandon Couillard with Jefferies. Please proceed with your question.
Brandon Couillard: Hi, thanks for the follow up. Just want to ask about your source of confidence in the pharma manufacturing business returning to growth in 2024. And whether that’d be a function of business with existing customers or new customers? Thanks.
Stephen Dilly: Hi, Brandon, as we look at the forecast that we’ve been developing internally, specifically on 2024, you see growth coming from the pipeline, which we think is an important driver, we also see a normalization of ordering patterns from some of our big customers as well. So they both are contributing. As we progress throughout this decade, you’ll see a bigger contribution of growth coming in from the pipeline. Like we said, this year has been sort of a reset year with PAXLOVID going away with one of our big products going through a recent product launch, which cause them to order prebuild inventory and then not order this year .Those patterns start to normalize. So we’re confident of growth both for marketed products, as well as on the pipeline.
Kevin Norrett: Maybe one other thing to add there, Brandon, I’ve been working a lot on is getting better at predicting that element. As well, we’ve added a couple of resources in the past six months here to be able to do better account management, follow up, et cetera, so that we can have a better perspective on the going forward forecasts. And you want to add there.
Stephen Dilly: Just to add, I think we saw that with our expectations on Q3 that we set in July that this would be the low quarter and that’s exactly what it turned out to be. And we’re expecting Q4 to come in line to meet our full year guidance. So I think as Kevin said, we felt much better about understanding the dynamics of this business than we did say a year ago.
Brandon Couillard: Thank you.
Operator: Thank you. There are no further questions at this time. I would like to turn the call back over to Stephen Dilly for his closing remarks.
Stephen Dilly: Well, thanks again for joining us today. And as you can tell Sri and Kevin and I looking forward to a very busy fall. We’ll be meeting many of you in person during our slate of. I think its five upcoming investor conferences over the next month or so. And of course, we also hope you’ll be able to join us for the Eco Synthesis focused virtual KOL event on December the 8th. And you’re thinking it’s going to be a fantastic conversation. So that’s all from us. And thank you very much for joining today.
Operator: This concludes today’s call. You may now disconnect.
